Biomea Fusion Reports Positive Phase 2 T1D Trial Results

The latest announcement is out from Biomea Fusion ( (BMEA) ).

On April 27, 2026, Biomea Fusion reported positive 52-week results from its Phase 2 COVALENT-112 trial of icovamenib in adults with Stage 3 type 1 diabetes, showing substantial and durable preservation of beta cell function after only 12 weeks of dosing. In patients diagnosed within three years, the 200 mg dose led to a 52% increase in mean C-peptide AUC at Week 12 and only a modest 7% decline from baseline by Week 52, while longer-standing patients (3–15 years since diagnosis) generally maintained C-peptide levels over the 52-week period with no new safety signals.

The results position icovamenib as a differentiated approach in T1D by targeting beta cell biology rather than immune suppression or cell transplantation, potentially expanding the treatment window beyond new-onset disease. Despite earlier FDA-related enrollment interruptions that halved the planned sample and prevented completion of the placebo-controlled portion, Biomea Fusion is moving ahead with a new Phase 2 study in recent-onset T1D at four major U.S. diabetes centers in the second half of 2026, aiming to test longer dosing at 200 mg and combination with an immunosuppressive agent to further enhance clinical benefit.

The most recent analyst rating on (BMEA) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Biomea Fusion stock, see the BMEA Stock Forecast page.

Spark’s Take on BMEA Stock

According to Spark, TipRanks’ AI Analyst, BMEA is a Neutral.

The score is held back primarily by weak financial performance (pre-revenue, ongoing losses, and negative free cash flow despite improved 2025 burn) and associated financing/dilution risk. Technicals are a key support with price above major moving averages and positive MACD, while corporate updates provide modest upside via upcoming clinical catalysts and stated runway. Valuation is moderately supportive via a low P/E, but there is no dividend yield.

To see Spark’s full report on BMEA stock, click here.

More about Biomea Fusion

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting beta cell biology for metabolic diseases, including type 1 and type 2 diabetes. Its lead candidate in diabetes, icovamenib, is an oral menin inhibitor intended as a short-course treatment to restore and preserve endogenous insulin production in patients with established disease.

Average Trading Volume: 1,422,381

Technical Sentiment Signal: Sell

Current Market Cap: $136.6M

See more data about BMEA stock on TipRanks’ Stock Analysis page.